Delivery Order SPE2DB24D2216-SPE2DB25FGPFV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,526.76 to AmerisourceBergen Drug Corp for 84 tablets of Xermelo 250 mg on July 23, 2025, with completion expected by August 13, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded procurement fulfilling pharmaceutical supply requirements for military healthcare systems. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $9,295.68 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the procurement of 84 boxes of Xermelo 250 mg tablets. The prime contractor will deliver the pharmaceutical products to a location in Conshohocken, Pennsylvania by July 21, 2023 in support of the Defense Logistics Agency's logistics and procurement operations. No set aside designation or subcontractors were identified. The delivery order was awarded under an existing...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a for-profit organization, to provide the pharmaceutical product XERMELO 250 MG TABLET 84S. The contract, valued at $19,160.74, has an ultimate completion date of April 9, 2024. Amerisourcebergen Drug Corp, through its Corporate Office division located in Conshohocken, Pennsylvania, is the prime contractor on this order. The contract is not associated with a larger vehicle and...
- This delivery order for $9,295.70, awarded by the Defense Logistics Agency to Amerisourcebergen Drug Corporation, is for the purchase of 84 boxes of XERMELO 250 MG tablets with a completion date of November 6, 2023. The contract has a firm fixed price and will be performed in Conshohocken, Pennsylvania by Amerisourcebergen Drug Corporation's Corporate Office as the prime contractor. No set-aside designation was used for this procurement. The Defense Logistics Agency supports America's armed...
- This federal contract award, with an ID of SPE2DB22D2206|SPE2DB25FGB40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,526.76 firm fixed-price delivery order contract, which runs through April 2, 2025, is for the supply of XERMELO 250 MG TABLET 84S, a medical product. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a...
- The federal contract award is a delivery order with a firm fixed price of $5,526.76 awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of XERMELO 250 MG TABLET 84S to the Defense Logistics Agency, a defense agency. The award has an ultimate completion date of July 28, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
- The federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order (DO) valued at $5,526.76 for the supply of XERMELO 250 MG TABLET 84S. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of February 4, 2025. This contract is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of XERMELO 250 MG TABLET 84S. The contract has a firm fixed price of $5,526.76 and a period of performance through July 23, 2025. This contract is not designated as a set-aside and is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, which provides...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a firm fixed price delivery order by the Defense Logistics Agency (DLA) to provide XERMELO 250 MG TABLET 84S for a potential value of $9,232.06. The contract has a completion date of March 1, 2024 and does not include a set-aside designation. Amerisourcebergen Drug Corp is the prime contractor and serves as a key supplier of pharmaceutical products and medical supplies to the Department of Defense under...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of XERMELO 250 MG TABLET 84S. The contract is a Firm Fixed Price contract with a ceiling value of $5,526.76 and a period of performance ending on July 7, 2025. The contract is not set aside and is an open competition. Amerisourcebergen Drug Corp is the prime contractor and there are no major subcontractors listed. The contract is...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPFVDelivery Order
The Defense Logistics Agency awarded a $5,526.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xermelo 250 mg tablets (84-count units). This non-set-aside competitive award is scheduled for completion by August 11, 2025, with performance to be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion vehicle running through December 2026 that provides comprehensive global pharmaceutical support to military healthcare programs and related federal medical systems. AmerisourceBergen Drug Corp, one of the nation's leading pharmaceutical distributors, maintains a significant federal procurement portfolio with the Defense Logistics Agency, supplying a diverse range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support military and veteran healthcare operations. The company's demonstrated capability to fulfill such orders through competitive procurement, combined with its status as a prime vendor under the DLA's pharmaceutical contracting framework, positions it as a critical supplier within the federal medical supply chain for defense healthcare initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 7/21/25 |